Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

417

Participants

Timeline

Start Date

March 22, 2021

Primary Completion Date

September 7, 2022

Study Completion Date

August 16, 2023

Conditions
Bipolar I Disorder
Interventions
DRUG

Iloperidone

Oral iloperidone

DRUG

Iloperidone Placebo

Oral placebo

Trial Locations (27)

1282

Vanda Investigational Site, Novi Iskar

3001

Vanda Investigational Site, Vratsa

5000

Vanda Investigational Site, Veliko Tarnovo

5047

Vanda Investigational Site, Tserova Koria

5500

Vanda Investigational Site, Lovech

6600

Vanda Investigational Site, Kardzhali

20877

Vanda Investigational Site, Gaithersburg

30030

Vanda Investigational Site, Decatur

30331

Vanda Investigational Site, Atlanta

33016

Vanda Investigational Site, Miami Lakes

33334

Vanda Investigational Site, Oakland Park

39232

Vanda Investigational Site, Flowood

44720

Vanda Investigational Site, North Canton

45417

Vanda Investigational Site, Dayton

72211

Vanda Investigational Site, Little Rock

72758

Vanda Investigational Site, Rogers

75080

Vanda Investigational Site, Richardson

75115

Vanda Investigational Site, DeSoto

78754

Vanda Investigational Site, Austin

89102

Vanda Investigational Site, Las Vegas

90230

Vanda Investigational Site, Culver City

90502

Vanda Investigational Site, Torrance

90703

Vanda Investigational Site, Cerritos

90806

Vanda Investigational Site, Long Beach

92868

Vanda Investigational Site, Orange

08053

Vanda Investigational Site, Marlton

95-080

Vanda Investigational Site, Tuszyn

Sponsors
All Listed Sponsors
lead

Vanda Pharmaceuticals

INDUSTRY